Investors Bancorp downgraded by Janney Montgomery Scott with a new price target
$ISBC
Savings Institutions
Finance
Janney Montgomery Scott downgraded Investors Bancorp from Buy to Neutral and set a new price target of $14.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2021 | $14.65 → $16.00 | Equal-Weight | Wells Fargo |
| 8/20/2021 | $15.50 → $17.50 | Equal-Weight → Overweight | Stephens & Co. |
| 7/30/2021 | $14.65 | Overweight → Equal-Weight | Wells Fargo |
| 7/29/2021 | $14.50 | Buy → Neutral | Janney Montgomery Scott |
SC 13G/A - Investors Bancorp, Inc. (0001594012) (Subject)
SC 13G - Investors Bancorp, Inc. (0001594012) (Subject)
SC 13G/A - Investors Bancorp, Inc. (0001594012) (Subject)
Wells Fargo reiterated coverage of Investors Bancorp with a rating of Equal-Weight and set a new price target of $16.00 from $14.65 previously
Stephens & Co. upgraded Investors Bancorp from Equal-Weight to Overweight and set a new price target of $17.50 from $15.50 previously
Wells Fargo downgraded Investors Bancorp from Overweight to Equal-Weight and set a new price target of $14.65
4 - Investors Bancorp, Inc. (0001594012) (Issuer)
4 - Investors Bancorp, Inc. (0001594012) (Issuer)
4 - Investors Bancorp, Inc. (0001594012) (Issuer)
15-12B - Investors Bancorp, Inc. (0001594012) (Filer)
8-K - Investors Bancorp, Inc. (0001594012) (Filer)
25-NSE - Investors Bancorp, Inc. (0001594012) (Subject)
SHORT HILLS, N.J., Jan. 26, 2022 /PRNewswire/ -- Investors Bancorp, Inc. (NASDAQ:ISBC) ("Company"), the holding company for Investors Bank ("Bank"), reported net income of $94.3 million, or $0.40 per diluted share, for the three months ended December 31, 2021 as compared to $66.9 million, or $0.28 per diluted share, for the three months ended September 30, 2021 and $75.1 million, or $0.32 per diluted share, for the three months ended December 31, 2020. For the year ended December 31, 2021, net income totaled $313.3 million, or $1.33 per diluted share, compared to $221.6 million, or $0.94 per diluted share, for the year ended December 31, 2020. The Company also announced today that its Board
SHORT HILLS, N.J., Jan. 5, 2022 /PRNewswire/ -- Investors Bancorp, Inc. (NASDAQ:ISBC), announced that it expects to report earnings for the fourth quarter ended December 31, 2021, on Wednesday, January 26, 2022 at approximately 5:00 p.m. Eastern Time (ET). A copy of the news release will be immediately available on its website, www.investorsbank.com. Investors Bancorp, Inc. is the holding company for Investors Bank. As of September 30, 2021, the Company reported assets of $27.32 billion and operated from its corporate headquarters in Short Hills, New Jersey and 154 branches located throughout New Jersey and New York. Contact: Marianne Wade Director, Financial Reporting 973-924-5100investorr
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2021. This quarter, there are constituent changes within five of our indexes: the KBW Nasdaq Capital Markets Index (Index Ticker: KSX), the KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), the KBW Nasdaq Financial Technology Index (Index Ticker: KFTX, ETF Ticker: FTEK.LN), the KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY) and
NEW YORK, April 4, 2022 /PRNewswire/ -- Arcus Biosciences Inc. (NYSE:RCUS) will replace Investors Bancorp Inc. (NASD:ISBC) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 7. S&P 500 constituent Citizens Financial Group Inc. (NYSE:CFG) is acquiring Investors Bancorp in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 7, 2022 S&P SmallCap 600 Addition Arcus Biosciences RCUS Health Care S&P SmallCap 600 Deletion Investors Bancorp ISBC Financials For m
PROVIDENCE, R.I. and SHORT HILLS, N.J., April 4, 2022 /PRNewswire/ -- Citizens Financial Group, Inc. (NYSE:CFG) ("Citizens") and Investors Bancorp, Inc. (NASDAQ:ISBC) ("Investors") today announce that the expected close date of the previously announced merger between the two companies is April 6, 2022, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the merger agreement. Citizens and Investors previously announced that regulatory approval for this merger was received from the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency. About Citizens Financial Group, Inc. Citizens Financial Group, Inc. is
Citizens Financial Group, Inc. (NYSE:CFG) ("Citizens") and Investors Bancorp, Inc. (NASDAQ:ISBC) ("Investors") today announce that the expected close date of the previously announced merger between the two companies is April 6, 2022, subject to the satisfaction or waiver of the remaining customary closing conditions set forth in the merger agreement. Citizens and Investors previously announced that regulatory approval for this merger was received from the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency. About Citizens Financial Group, Inc. Citizens Financial Group, Inc. is one of the nation's oldest and largest financial institutions, wi
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy Patients Theravance Biopharma, Inc. (NASDAQ:TBPH) announced results from the second Phase 3 study, assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension. The primary endpoint was not statistically significant for the overall population of patients, which included patients with Parkinson's disease, pure autonomic failure and multiple system atrophy. Yet the pre-specified subgroup analysis by disease
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20220404-1451281/1451281_isbc6.pdf